Effect of bone marrow-derived mesenchymal stromal cells on hepatoma

Cytotherapy

Volumn 16, Issue 9, 2014, Pages 1197-1206

  Abd Allah, Somia H ^a   Shalaby, Sally M ^a   El Shal, Amal S ^a   Elkader, Eman Abd ^a   Hussein, Samia ^a   Emam, Emad ^a   Mazen, Nehad F ^a   El Kateb, Mohammed ^a   Atfy, Mha ^b  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b Zagazig University   (Egypt)

Author keywords

Apoptosis; Gene expression; Hepatocellular carcinoma; MSCs

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BETA ACTIN; CASPASE 3; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; SURVIVIN; TESTIS DETERMINING FACTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIARY CIRRHOSIS; BONE MARROW DERIVED MESENCHYMAL STROMAL CELL; CANCER CELL; CELL DEATH; CELL PROLIFERATION; DOWN REGULATION; DYSPLASIA; FEMALE; GENE CONTROL; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HEPATOCELLULAR CARCINOMA CELL LINE; HISTOPATHOLOGY; HOUSEKEEPING GENE; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LIVER CELL CARCINOMA; MESENCHYMAL STROMA CELL; METHYL THIAZOLYL TETRAZOLIUM ASSAY; MITOSIS INHIBITION; MOUSE; MURINE MODEL; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; TUMOR GROWTH; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL GROWTH; GENETICS; HUMAN; LIVER; LIVER NEOPLASMS; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

MURINAE; MUS;

ANIMALS; APOPTOSIS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER; LIVER NEOPLASMS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84905561289     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.05.006     Document Type: Article

References (51)

1. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006, 118:3030-3044.
2. Kanwal F., Hoang T., Kramer J.R. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011, 140:1182-1188.
3. Petta S., Craxi A. Hepatocellular carcinoma and nonalcoholic fatty liver disease: from a clinical to a molecular association. Curr Pharm Des 2010, 16:741-752.
4. Page J.M., Harrison S.A. NASH and HCC. Clin Liver Dis 2009, 13:631-647.
5. Amarapurkar D.N., Patel N.D., Kamani P.M. Impact of diabetes mellitus on outcome of HCC. Ann Hepatol 2008, 7:148-151.
6. Morita K., Taketomi A., Soejima Y. De novo hepatocellular carcinoma in a liver graft with sustained hepatitis C virus clearance after living donor liver transplantation. Liver Transpl 2009, 15:1412-1416.
7. Liovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
8. Bluteau O., Jeannot E., Bioulac-Sage P. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002, 32:312-315.
9. Camma C., Giunta M., Andreone P., Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence based approach. J Hepatol 2001, 34:593-602.
10. Guo J.T., Zhou H., Liu C., Aldrich C., Saputelli J., Whitaker T. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections. J Virol 2000, 74:1495-1505.
11. Liang T.J., Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 2004, 127:S62-71.
12. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009, 15:513-520.
13. Wulf G.G., Chapuy B., Trumper L. Mesenchymal stem cells from bone marrow: phenotype, aspects of biology, and clinical perspectives. Med Klin 2006, 101:408-413.
14. Menon L.G., Picinich S., Koneru R. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells 2007, 25:520-528.
15. Willert K., Jones K.A. Wnt signalling: is the party in the nucleus?. Genes Dev 2006, 20:1394-1404.
16. Yang Y.A., Zhang G.M., Feigenbaum L., Zhang Y.E. Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell 2006, 9:445-457.
17. Joubert A., Bianchi P., Maritz C. Influence of prostaglandinA2 on Bax, Bcl-2 and PCNA expression in MCF-7 cells. Biomed Res 2006, 27:157-162.
18. Khakoo A.Y., Pati S., Anderson S.A., Reid W., Elshal M.F., Rovira, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006, 203:1235-1247.
19. Ramasamy R., Lam E.W., Soeiro I., Tisato V., Bonnet D., Dazzi F. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 2007, 21:304-310.
20. Pulavendran S., Vignesh J., Rose C. Differential anti-inflammatory and antifibrotic activity of transplanted mesenchymal vs hematopoietic stem cells in carbon tetrachloride-induced liver injury in mice. Int Immunopharmacol 2010, 10:513-519.
21. Calabro L., Fonsatti E., Bellomo G., Alonci A., Colizzi F., Sigalotti L., et al. Differential levels of soluble endoglin (CD105) in myeloid malignancies. J Cell Physiol 2003, 194:171-175.
22. Lu Y.R., Yuan Y., Wang X.J. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther 2008, 7:245-251.
23. Pulavendran S., Rose C., Mandal A.B. Hepatocyte growth factor incorporated chitosan nanoparticles augment the differentiation of stem cell into hepatocytes for the recovery of liver cirrhosis in mice. J Nanobiotechnol 2011, 9:15.
24. Blomme B., Steenkiste C.V., Grassi P., Haslam S.M., Dell A., Callewaert N., et al. Alterations of serum protein N-glycosylation in two mouse models of chronic liver disease are hepatocyte and not B cell driven. Am J Physiol Gastrointest Liver Physiol 2011, 300:G833-G842.
25. Kroger A., Ortmann D., Krohne T.U., Mohr L., Blum H.E., Hauser H., et al. Growth suppression of the hepatocellular carcinoma cell line Hepa1-6 by an activatable interferon regulatory factor-1 in Mice. Cancer Res 2001, 61:2609-2617.
26. Bancroft J.D., Gamble M. Theory and Practice of Histological Techniques 2002, 125-138. Churchill Livingstone, New York/London/Philadelphia. 5th edition.
27. Whittaker S., Marais R., Zhu A.X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010, 29:4989-5005.
28. Kornek M., Raskopf E., Tolba R., Becker U., Klöckner M., Sauerbruch T., et al. Accelerated orthotopic hepatocellular carcinomas growth is linked to increased expression of pro-angiogenic and prometastatic factors in murine liver fibrosis. Liver Int 2008, 28:509-518.
29. Schwartz R.E., Reyes M., Koodie L. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 2002, 109:1291-1302.
30. Vucur M., Roderburg C., Bettermann K., Tacke F., Heikenwalder M., Trautwein C., et al. Mouse models of hepatocarcinogenesis: What can we learn for the prevention of human hepatocellular carcinoma?. Oncotarget 2010, 1:373-378.
31. Abdel Aziz M.T., El Asmar M.F., Atta H.M., Mahfouz S., Fouad H.H., Roshdy N.K., et al. Efficacy of mesenchymal stem cells in suppression of hepatocarcinorigenesis in rats: possible role of Wnt signaling. J Exp Clin Cancer Res 2011, 5(30):49.
32. Qiao L., Xu Z., Zhao Z. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res 2008, 18:500-507.
33. Kidd S., Spaeth E., Klopp A., Andreeff M., Hall B., Marini F.C. The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy 2008, 10:657-667.
34. Ma B., Jiang H., Jia J., Di L., Song G., Yu J., Zhu Y., Lu Z., et al. Murine bone marrow stromal cells pulsed with homologous tumor-derived exosomes inhibit proliferation of liver cancer cells. Clin Transl Oncol 2012, 14:764-773.
35. Hall B., Dembinski J., Sasser A.K., Studeny M., Andreeff M., Marini F. Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. Int J Hematol 2007, 86:8-16.
36. Nakamizo A., Marini F., Amano T., Khan A., Studeny M., Gumin J., et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005, 65:3307-3318.
37. Sakaida I., Terai S., Yamamoto N. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 2004, 40:1304-1311.
38. Abdel Aziz M.T., Atta H., Roshdy N.K. Role of SDF-1/CXCR4 axis in stem cell homing in the mouse model of induced lung fibrosis. Int J Biotech Biochem 2010, 6:625-644.
39. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22:8581-8589.
40. Gregory C.A., Singh H., Perry A.S., Prockop D.J. The Wnt signalling inhibitor Dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol Chem 2003, 278:28067-28078.
41. Zhu Y., Sun Z., Han Q., Liao L., Wang J., Bian C., et al. Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia 2009, 23:925-933.
42. Qiao L., Xu Z.L., Tan X. Investigation of inhibition of Wnt/β-catenin pathway in breast cancer cells mediated by Dkk-1 released from human mesenchymal stem cells. Prog Biochem Biophys 2007, 34:702-708.
43. Djouad F., Bony C., Apparailly F., Pascale L.P., Christian J., Noel D. Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation 2006, 82:1060-1066.
44. Sun X.Y., Nong J., Qin K., Lu H., Moniri M.R., Dai L.J., et al. MSC (TRAIL)-mediated HepG2 cell death in direct and indirect co-cultures. Cancer Res 2011, 31:3705-3712.
45. Ohlsson L.B., Varas L., Kjellman C., Edvardsen K., Lindvall M. Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Exp Mol Pathol 2003, 75:248-255.
46. Ganta C., Chiyo D., Ayuzawa R., Rachakatla R., Pyle M., Andrews G., et al. Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation. Cancer Res 2009, 69:1815-1820.
47. Tian K., Yang S., Ren Q., Han Z., Lu S., Ma F., et al. p38 MAPK contributes to the growth inhibition of leukaemic tumor cells mediated by human umbilical cord mesenchymal stem cells. Cell Physiol Biochem 2010, 26:799-808.
48. Kucerova L., Matuskova M., Hlubinova K., Altanerova V., Altaner C. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer 2010, 9:129.
49. Kurtova A.V., Balakrishnan K., Chen R., Ding W., Schnabl S., Quiroga M.P., et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009, 114:4441-4450.
50. Vianello F., Villanova F., Tisato V., Lymperi S., Ho K.K., Gomes A.R., et al. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. Haematologica 2010, 95:1081-1089.
51. Li L., Tian H., Yue W.M., Zhu F., Li S.H., Li W.J. Human mesenchymal stem cells play a dual role on tumor cell growth in vitro and in vivo. J Cell Physiol 2011, 226:1860-1867.